| Name | Title | Contact Details |
|---|
ePayPolicy is the fastest, easiest and most secure way to move money in the insurance industry. Its never been easier to get paid. There are no contracts, no setup fees, and no hidden fees. Best of all, there is no technical work required to get up and running. Sign up takes only 5 minutes at epaypolicy.com and well have you ready to accept payments online within 24 hours.
TD Bank is a Canada-based financial institution that provides personal and commercial banking products and services for individuals and businesses.
Geofabrica is a manufacturing technology development company specializing in customized additive manufacturing systems for factory and expeditionary applications. We build innovative solutions to unlock the economic and production potential of 3D printing and additive technologies for metal, plastic, and composite applications. We create application-specific devices and processes to help customers overcome the limitations of current technologies and help them achieve a competitive advantage within the evolving digital manufacturing landscape. ITAR registered, JCP certified, NIST 800-171 compliant.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.